Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases
Pharmaceutics · 15.06.2023 · 15 (6) · 1746
DOI: 10.3390/pharmaceutics15061746 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 15.06.2023. Verfasst von Mahmoud Mostafa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minya 61519, Egypt. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 512 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Khalid University, Deanship of Scientific Research at King Khalid University.
Abstract (Originalsprache)
Chronic ocular diseases can seriously impact the eyes and could potentially result in blindness or serious vision loss. According to the most recent data from the WHO, there are more than 2 billion visually impaired people in the world. Therefore, it is pivotal to develop more sophisticated, long-acting drug delivery systems/devices to treat chronic eye conditions. This review covers several drug delivery nanocarriers that can control chronic eye disorders non-invasively. However, most of the developed nanocarriers are still in preclinical or clinical stages. Long-acting drug delivery systems, such as inserts and implants, constitute the majority of the clinically used methods for the treatment of chronic eye diseases due to their steady state release, persistent therapeutic activity, and ability to bypass most ocular barriers. However, implants are considered invasive drug delivery technologies, especially those that are nonbiodegradable. Furthermore, in vitro characterization approaches, although useful, are limited in mimicking or truly representing the in vivo environment. This review focuses on long-acting drug delivery systems (LADDS), particularly implantable drug delivery systems (IDDS), their formulation, methods of characterization, and clinical application for the treatment of eye diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minya 61519, Egypt.
- Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62223, Saudi Arabia.
- School of Pharmacy, Kingston University London, Kingston Upon Tames KT1 2EE, UK.
- School of Pharmacy, The University of Auckland, Auckland 1010, New Zealand.
ORCID-Profile: Mahmoud Mostafa, Adel Al Fatease, Raid G Alany, Hamdy Abdelkader
Förderung
- King Khalid University
- Deanship of Scientific Research at King Khalid University
Zitieren
APA
Mostafa, M., Al Fatease, A., Alany, R. G., & Abdelkader, H. (2023). Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases. Pharmaceutics, 15(6), 1746. https://doi.org/10.3390/pharmaceutics15061746
Vancouver
Mostafa M, Al Fatease A, Alany RG, Abdelkader H. Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases. Pharmaceutics. 2023;15(6):1746. doi:10.3390/pharmaceutics15061746
BibTeX
@article{Mostafa2023,
author = {Mostafa, Mahmoud and Al Fatease, Adel and Alany, Raid G and Abdelkader, Hamdy},
title = {Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {6},
pages = {1746},
doi = {10.3390/pharmaceutics15061746}
}
EUVIMED